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Human surfactant protein-D (SP-D), an innate immune pattern recognition soluble factor, 
is known to modulate a range of cytokines and chemokines, such as TNF-α and TGF-β at 
mucosal surfaces during infection, allergy, and inflammation. A recent study has shown 
that treatment with a recombinant fragment of human SP-D (rfhSP-D) for 48 h induces 
apoptosis in pancreatic cancer cells. Our hypothesis is that at earlier time points, SP-D 
can also influence key cytokines as a part of its putative role in the immune surveillance 
against pancreatic cancer, where the inflammatory tumor microenvironment contributes 
to the epithelial-to-mesenchymal transition (EMT), invasion, and metastasis. Here, we 
provide the first evidence that rfhSP-D can suppress the invasive-mesenchymal proper-
ties of highly aggressive pancreatic cancer cells. Mechanistically, rfhSP-D inhibited TGF-β 
expression in a range of pancreatic cancer cell lines, Panc-1, MiaPaCa-2, and Capan-2, 
thereby reducing their invasive potential. Smad2/3 expression diminished in the cyto-
plasm of rfhSP-D-treated cells as compared to the untreated control, suggesting that an 
interrupted signal transduction negatively affected the transcription of key mesenchymal 
genes. Thus, expressions of Vimentin, Zeb1, and Snail were found to be downregulated 
upon rfhSP-D treatment in the pancreatic cancer cell lines. Furthermore, blocking TGF-β 
with neutralizing antibody showed similar downregulation of mesenchymal markers as 
seen with rfhSP-D treatment. This study highlights yet another novel innate immune 
surveillance role of SP-D where it interferes with EMT induction by attenuating TGF-β 
pathway in pancreatic cancer.
Keywords: surfactant protein, surfactant protein-D, pancreatic cancer, epithelial-to-mesenchymal transition, 
metastasis, transformation growth factor
inTrODUcTiOn
Pancreatic ductal adenocarcinoma (PDA) is one of the most lethal of all human malignancies 
with a dismal 5-year survival rate of below 7%; it is estimated to become the third leading cause 
of cancer-related death by 2030 (1). PDA is associated with a high rate of mortality due to meta-
stasis, resistance to conventional chemotherapy, and high tumor recurrence rate after surgery (2). 
Metastasis requires epithelial-to-mesenchymal transition (EMT), which is considered a principal 
cause of tumor recurrence and resistance to conventional therapies (3–6). EMT is a complex and 
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hierarchical process during tumor progression; it enables the 
tumor cells to acquire increased motility, leading to invasion 
of adjoining tissue and infiltration to systemic circulation and 
subsequent penetration into the adjacent tissues, resulting 
in macroscopic secondary tumors (7, 8). A number of EMT 
markers appear to regulate the invasion-metastasis process in 
the pancreatic tumor cells. Aberrant activation of EMT has 
been attributed to over-expression of mesenchymal markers, 
such as Zeb1 (zinc finger E-box binding homeobox 1) (9), Snail 
(10), and Vimentin (10), as well as repression of E-cadherin, 
an epithelial marker (6) in the pancreatic cancer cells. During 
the EMT process, E-cadherin expression is lost whereas mesen-
chymal markers, including fibronectin and Vimentin, are over-
expressed (11). Markers, such as Snail, Slug, Zeb1, Zeb2, and 
Twist, to name a few, have been shown to suppress E-cadherin. 
E-cadherin gene-deficient mice do not survive past implanta-
tion (12). The Snail-expressing metastatic tumors are associated 
with poor prognosis, and drug and immune resistance, offering 
limited opportunity for therapeutic intervention (12).
Recent studies have shown that an inflammatory tumor 
microenvironment influences early tumor dissemination, EMT, 
and metastasis in pancreatic cancer (5, 6, 13). Pro-tumorigenic 
cytokines, including TGF-β, have also been linked to EMT, inva-
sion, metastasis, and drug-resistance in many types of cancer 
(14, 15). In PDA, elevated TGF-β expression has been associ-
ated with a highly invasive (metastatic) phenotype, acquired 
through SMAD signaling. Importantly, TGF-β signaling regu-
lates EMT-gene signatures, thereby promoting cell motility and 
invasiveness in the pancreatic cancer cells (8, 16–19).
Human surfactant protein-D (SP-D), a soluble collagen 
containing C-type lectin (collectin), is a potent innate immune 
molecule, found at the pulmonary and extra-pulmonary mucosal 
surfaces. While acting as a link between innate and adaptive 
immunity, SP-D is known for its role in immune surveillance 
and immunomodulation in infection and allergy (20). SP-D has 
been considered for quite some time as a modulator of inflam-
matory response. However, recent studies have shown its anti-
proliferative properties against cancer cells (21, 22). In addition, 
SP-D deficiency in animal models has been shown to trigger 
serious adverse pathological consequences as in emphysema (23), 
chronic and infectious lung diseases (24–26), Crohn’s disease, and 
ulcerative colitis (27). A new dimension to the defense mecha-
nism attributable to SP-D became evident when a recombinant 
fragment of human SP-D (rfhSP-D) comprising homotrimeric 
neck region and carbohydrate recognition domain (rfhSP-D) 
was found to selectively induce apoptosis in the sensitized eosino-
phils derived from allergic patients, whereas eosinophils derived 
from healthy individuals were unaffected (28). Proteomics 
analysis of an eosinophil-like leukemic cell line (AML14.3D10), 
treated with rfhSP-D, showed that it caused cell cycle arrest 
via activation of G2/M checkpoints, and subsequently induced 
apoptosis via p53 pathway (21). Treatment of human lung adeno-
carcinoma A549 cell line with SP-D has been shown to suppress 
the epidermal growth factor (EGF) signaling by interrupting the 
EGF–EGFR interaction, thus reducing cell proliferation, inva-
sion, and migration (22). Recently, Kaur et al. have shown that 
treatment with rfhSP-D for 48 h differentially induced apoptosis 
in pancreatic cancer cell lines, such as Panc-1, MiaPaCa-2, and 
Capan-2 via Fas-mediated pathway, involving cleavage of caspase 
8 and 3 (29).
In this study, we demonstrate, for the first time, an early 
anti-tumorigenic role of rfhSP-D, where it suppresses the 
EMT and invasive-mesenchymal phenotype in pancreatic 
cancer cell lines. We show that rfhSP-D inhibits the invasive 
functions of TGF-β/SMAD expressing pancreatic cancer cells. 
Mechanistically, rfhSP-D downregulates the EMT-related gene 
signatures (Vimentin, Zeb1, and Snail), and hence, pancreatic 




Human pancreatic cancer cell lines, such as Panc-1 (CRL-1469), 
MiaPaCa-2 (CRL-1420), and Capan-2 (HTB-80), were obtained 
from ATCC, and used as an in vitro model in this study. All cell 
lines were cultured in DMEM-F12 media supplemented with 
2 mM l-glutamine, 10% v/v fetal calf serum (FCS), and penicil-
lin (100 units/ml)/streptomycin (100 µg/ml) (Thermo Fisher). All 
cell lines were grown at 37°C under 5% v/v CO2 until 80–90% 
confluency was attained.
expression and Purification of rfhsP-D
Expression and purification of a recombinant form of human 
SP-D was carried out as reported previously (28). Plasmid pUK-D1 
(containing cDNA sequences for 8 Gly-X-Y repeats, neck and CRD 
region of human SP-D) was transformed into Escherichia coli 
BL21 (λDE3) pLysS strain (Invitrogen). A single colony was 
inoculated in 25  ml of Luria–Bertani (LB) medium contain-
ing ampicillin (100  µg/ml) and chloramphenicol (34  µg/ml) 
(Sigma-Aldrich) at 37°C on a shaker overnight. The overnight 
inoculum was grown in a 1 l LB medium (containing ampicillin 
and chloramphenicol) until the OD600 reached 0.6, induced with 
0.4 mM isopropyl β-D-thiogalactoside (IPTG) (Sigma-Aldrich, 
UK) for 3 h at 37°C on an orbital shaker, and then centrifuged 
(5,000  ×  g, 4°C, 15  min). The bacterial cell pellet was lysed 
using 50 ml of lysis buffer (50 mM Tris–HCl, pH 7.5, 200 mM 
NaCl, 5 mM EDTA, pH 7.5) containing lysozyme (100 µg/ml; 
Sigma-Aldrich) and 0.1  mM phenylmethylsulfonyl fluoride 
(PMSF; Sigma-Aldrich, UK) at 4°C for 1 h. The bacterial cell 
suspension was sonicated at 60  Hz for 30  s with an interval 
of 2  min each (15 cycles) and centrifuged at 13,800  ×  g for 
15 min at 4°C. The pellet containing insoluble rfhSP-D as inclu-
sion bodies was suspended in 25  ml of solubilization buffer 
(50  mM Tris–HCl, pH 7.5, 100  mM NaCl, 5  mM EDTA, pH 
7.5) containing 6 M urea at 4°C for 1 h and then centrifuged 
at 13,800 × g at 4°C for 15 min. The supernatant was serially 
dialyzed against solubilization buffer containing 4, 2, 1, and 0 M 
urea and 10 mM β-mercaptoethanol for 2 h at 4°C, followed by 
final dialysis in solubilization buffer containing 5  mM CaCl2 
(Affinity buffer) for 3 h and centrifuged at 13,800 × g, 4°C for 
15 min. The supernatant containing soluble rfhSP-D was passed 
through a 5 ml Maltose-Agarose column (Sigma-Aldrich). The 
Table 1 | Target genes and terminal primers used in the qPCR analysis.
gene Forward primer reverse primer
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affinity-column was washed extensively using affinity buffer 
containing 1 M NaCl (20 ml) before eluting the bound rfhSP-D 
protein with solubilization buffer containing 10 mM EDTA, pH 
7.5. The concentration of the eluted protein was determined 
via OD280. The peak fractions were passed through Pierce™ 
High Capacity Endotoxin Removal Resin (Qiagen) to remove 
lipopolysaccharide (LPS). Endotoxin levels were determined 
using the QCL-1000 Limulus amebocyte lysate system (Lonza); 
the assay was linear over a range of 0.1–1.0 EU/ml (10 EU = 1 ng 
of endotoxin). The amount of endotoxin levels was found to be 
<4 pg/μg of the rfhSP-D protein.
cell Morphological studies
Morphological alterations were examined in order to determine 
the optimal dose of rfhSP-D for the treatment of pancreatic 
cell lines. Panc-1 cells were seeded at a low density (0.1 × 104) 
and grown overnight in DMEM-F12 containing 10% FCS in 
a 12-well plate (Nunc). The cells were washed twice with PBS 
and incubated in serum-free medium with and without rfhSP-D 
(5, 10, or 20 µg/ml). An area of 5–10 cells was selected for each 
treatment condition for analysis at 0, 6, and 24  h using phase 
contrast Axioscope microscope.
Matrigel invasion assay
The invasion assay was performed using Corning™ BioCoat™ 
Matrigel™ Invasion Chamber (BD Matrigel Matrix). Inserts, 
pre-coated with basement membrane that was extracted from 
Engelbreth-Holm-Swarm mouse tumor, were reconstituted 
in serum-free DMEM-F12 at 37°C for 2 h. 35,000 cells, re-
suspended in 500 µl serum-free DMEM-F12, were added to the 
top wells of the inserts with and without rfhSP-D (20 µg/ml), 
and 500 µl of medium containing serum was added to the bot-
tom of the inserts in a 24-well plate and incubated at 37°C for 
22 h. Next, medium containing non-evaded cells were discarded 
and remaining cells were scraped off from the membrane 
using a sterile cotton bud, ensuring cells at the bottom of the 
membrane remained intact for fixing. Fixation was done using 
100% methanol for 2 min, followed by 2 min incubation with 
toluidine blue to stain the evaded cells. The membrane was cut 
using a sterile scalpel and mounted on the slide to count the 
evaded cells.
Fluorescence Microscopy
Cells (0.5 ×  105) were grown on coverslips overnight at 37°C 
under 5% v/v CO2. Next day, cells were washed three times with 
sterile PBS before being incubated with and without rfhSP-D 
(5, 10, or 20 µg/ml) in a serum-free DMEM-F12 for 1 h for rfhSP-D 
binding to the cells, and 12 or 24 h for intracellular staining. 
The coverslips were washed three times with PBS in between 
each step. For rfhSP-D binding analysis, the coverslips were 
incubated for 1  h with mouse anti-human SP-D (a kind gift 
from Prof. U. Holmskov, Odnese, Denmark; 1:200) followed by 
goat anti-mouse IgG H&L (Cy5 ®, 1:500; Abcam) and Hoechst 
(1:10,000; Thermo Fisher) for immunofluorescence analysis. 
For the intracellular staining (Vimentin, Zeb1, E-Cadherin, 
SP-D, and TGF-β), the cells were fixed and permeabilized 
using ice-cold 100% methanol at −20°C for 10 min. This was 
followed by 1  h incubation with rabbit anti-human IgG anti-
body (Vimentin, Zeb1, and TGF-β) (1:500; Cell Signaling) and 
human SP-D (1:500), and another 1  h incubation with Alexa 
Fluor 488 (1:500; Thermo Fisher) and Hoechst (1:10,000; 
Thermo Fisher) for immunofluorescence analysis. For human 
pancreatic tissue, immunofluorescence was performed as 
described previously (30). Immunostaining was visualized 
using confocal laser-scanning microscope (Olympus). The 
human pancreatic tissue was obtained from the Department 
of Pathology, Philipps-University of Marburg, Germany fol-
lowing ethical conside rations as stipulated by the University’s 
ethical guidelines.
Quantitative rT-Pcr
Pancreatic cancer cell lines were incubated with either rfhSP-
D (20  µg/ml) or anti-TGF-β neutralizing antibody (Thermo 
Fisher) for various time points and the centrifuged cell pellets 
were stored at −80°C. Total RNA was extracted using GenElute 
Mammalian Total RNA Purification Kit (Sigma-Aldrich, UK), 
followed by DNase I treatment to remove any DNA impurities. 
The concentration and purity of total RNA were determined 
by measuring the absorbance at 260 nm and 260:280 nm ratio, 
respectively, using NanoDrop 2000/2000c (Thermo-Fisher 
Scientific). Total RNA (2  µg) was used to synthesize cDNA 
using High Capacity RNA to cDNA Kit (Applied Biosystems). 
The web-based Basic Local Alignment Search Tool and 
Primer-BLAST (http://blast.ncbi.nlm.nih.gov/Blast.cgi) were 
used to design the forward and reverse primer sequences 
(Table 1).
Each qPCR reaction, carried out in triplicates, consisted 
of 5  µl Power SYBR Green MasterMix (Applied Biosystems), 
75  nM of forward and reverse primers, and 500  ng cDNA, 
making up to a 10  µl final volume per well. Relative mRNA 
expression was analyzed using 7900HT Fast Real-Time PCR 
System (Applied Biosystems). Samples were initially incubated 
at 50°C (2 min) and 95°C (10 min), followed by amplification 
of the template for 40 cycles (each cycle for 15  s at 95°C and 
1 min at 60°C). Human 18S RNA, an endogenous control, was 
used to normalize the gene expressions. The cycle threshold (Ct) 
mean value for each target gene was used to calculate the rela-
tive expression using the relative quantification (RQ) value and 
FigUre 2 | Recombinant fragment of human SP-D (rfhSP-D) expression  
and purification. Escherichia coli BL21 (λDE3) pLysS containing pUK-D1  
was induced with IPTG. The expressed bacterial cells show rfhSP-D 
over-expression at ~20 kDa as compared to un-induced cells. The insoluble 
inclusion bodies were refolded and affinity purified on maltose-agarose. The 
peak fractions shown here appeared homogenous on a 12% SDS-PAGE.
FigUre 1 | Human pancreatic cancer tissue expressing SP-D and Vimentin. 
Double immunofluorescence staining of SP-D (green), Vimentin (red), and 
DAPI (blue) in four different areas of representative human pancreatic cancer 
tissue. Scale bars, 50 µm.
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formula: RQ  =  2−ΔΔCt, which was compared with the relative 
expression of the untreated cells.
Western blot
Cells (0.1  ×  107) were cultured in a 6-well plate (Nunc) and 
incubated with and without rfhSP-D (20 µg/ml) in a serum-free 
DMEM-F12 for various time points. The cells were then mixed 
with 2× treatment buffer (50  mM Tris–HCL pH 6.8, 2% v/v 
β-merceptoethanol, 2% v/v SDS, 0.1% w/v bromophenol blue, 
and 10% v/v glycerol) and sonicated for 30 s before running on 
a SDS-PAGE (12% w/v) for 90  min at 120  V. The SDS-PAGE 
separated proteins were electrophoretically transferred onto a 
nitrocellulose membrane using an iBlot 7-min Blotting System 
(Thermo Fisher), followed by blocking with 5% w/v non-fat 
dried milk powder (Sigma) in 100 ml PBS for 2 h on a rotatory 
shaker at room temperature. The membrane was washed with 
PBST (PBS + 0.05% Tween 20) three times, each time for 10 min. 
The membrane was then incubated with primary anti-human 
TGF-β antibody, (1:1,000; R&D systems) at 4°C overnight 
on a rotatory shaker, followed by secondary anti-rabbit IgG 
horseradish pero xidase-conjugate (1:1,000; Promega) for 1 h at 
room temperature. The positive bands were visualized using 3,3′- 
diaminobenzidine (DAB) substrate kit (Thermo Fisher).
statistical analysis
Graphs were made and statistically analyzed using an unpaired 
one-way or two-way ANOVA tests in Graphpad Prism 6.0. 
Significant values were considered based on *p < 0.05, **p < 0.01, 
***p < 0.001, and ****p < 0.0001 between treated and untreated 
samples. Error bars show the SEM, as indicated in the figure 
legends.
resUlTs
Presence of sP-D can be Detected  
in human Pancreatic cancer Tissues
Immunofluorescence studies of human pancreatic cancer tissues 
probed with anti-human SP-D monoclonal antibody showed 
positive staining, confirming the presence of SP-D in the tissues 
(Figure  1). Additionally, the tissues were probed with anti-
Vimentin, which also showed positive staining. However, we 
could not detect or purify SP-D from the culture supernatants 
of all three pancreatic cancer cell lines (data not shown). It is 
possible that the SP-D staining pertains to the tumor micro-
environment. Thus, we proceeded to test the effect of exogenous 
rfhSP-D (Figure 2) on cultured pancreatic cancer cell lines.
rfhsP-D induces Morphological 
alterations in the Pancreatic  
cancer cell line, Panc-1
To determine the optimal dose of rfhSP-D, Panc-1 cells were 
incubated with 5, 10, and 20 µg/ml for up to 24 h. The colonies 
of 10–15 cells were selected for each protein dose to observe 
the effect of rfhSP-D on cell morphology and cell division. The 
images of the selected cell colonies were taken at 0, 6, and 24 h 
(Figure 3). Untreated Panc-1 cells, as well as those treated with 
rfhSP-D (5  µg/ml), acquired spindle-type cell morphology, 
reduced cell–cell contact, and continued to divide in a time-
dependent manner. However, Panc-1 cells, treated with 10 and 
20 µg/ml concentration of rfhSP-D, did not acquire spindle shape 
and appeared to be static. However, cell morphology at 10 µg/ml 
appeared to be regaining the spindle shape and reduced cell–cell 
FigUre 3 | Morphological changes in Panc-1 cells following rfhSP-D treatment. Panc-1 cells (0.1 × 104) were grown overnight in a 12-well plate tissue culture and 
colonies of 5–10 cells were selected for analysis with and without rfhSP-D (5, 10, and 20 µg/ml) at 0, 6, and 24 h. The cells treated with 5 µg/ml and untreated 
appeared to undergo epithelial-to-mesenchymal transition as they acquired spindle shape and showed reduced cell–cell contact, whereas cells treated with 10 and 
20 µg/ml appeared static and did not acquire spindle shape.
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contact, with some evidence of cell division by 24 h. At 20 µg/ml, 
the non-spindle effect continued up to 24 h. Although some cell 
division was noted, cells remained in close contact with each 
other and static. Therefore, 20 µg/ml dose of rfhSP-D was selected 
to investigate its possible effect on EMT and invasion involving 
Panc-1, MiaPaCa-2, and Capan-2 cells.
rfhsP-D suppresses the invasive capacity 
of the Pancreatic cancer cell lines
The matrigel invasive chambers, pre-coated with extracellular 
matrix proteins, were used to incubate the pancreatic cancer cells 
(3.5 × 104) in the presence and absence of rfhSP-D (20 µg/ml) in 
the upper surface of the chamber; serum containing DMEM-F12 
was used as a chemo-attractant in the bottom surface for 22  h. 
Both Panc-1 and MiaPaCa-2 cell lines, treated with rfhSP-D, 
showed significantly reduced invasion in the matrigel (Figure 4A); 
however, almost no invasion occurred in Capan-2 whether rfhSP-
D treated or untreated. This was anticipated since Capan-2 is a 
low-grade cancer cell line. MiaPaCa-2 was most affected as the 
invasion was reduced by 65%, followed by Panc-1 cell line, which 
was approximately 50% less than the untreated cells (Figure 4B). 
Since pancreatic cancer cells are well known to overexpress TGF-β, 
which has a prominent-role in inducing EMT, the expression of 
TGF-β in the pancreatic cell lines was investigated following the 
treatment with rfhSP-D (20 µg/ml).
rfhsP-D Downregulates TgF-β gene 
expression in Pancreatic cancer cells
The transcriptional expression of TGF-β was significantly down re-
g ulated in Panc-1 (~log10 0.5-fold) and MiaPaCa-2 (~log10 0.3-
fold) at 12 h (Figure 5A), whereas Capan-2 showed no difference 
following rfhSP-D treatment. This suggested that reduced TGF-β 
transcripts were being made following the rfhSP-D treatment. 
Thus, the total cell extracts for all cell lines were analyzed by 
Western blot using anti-human TGF-β monoclonal antibody, 
which revealed a reduction in the amount of TGF-β (~60 kDa 
band) in the rfhSP-D-treated Panc-1 and MiaPaCa-2 samples, as 
compared to the untreated cells; the amount of TGF-β in Capan-2 
was unaffected (Figure 5B). The qualitative analysis by immuno-
fluorescence microscopy showed that TGF-β expression at 24 h 
diminished considerably within the cytoplasm of Panc-1 and 
MiaPaCa-2 cell lines following rfhSP-D treatment (Figure 5C); 
however, this was not evident in the case of Capan-2 cells (result 
not shown). During TGF-β induced EMT pathway, Smad2/3 are 
phosphorylated in the cytoplasm, followed by translocation into 
nucleus; however, Smad2/3 staining appeared very weak in the 
FigUre 4 | Recombinant fragment of human SP-D (rfhSP-D) supresses invasiveness in pancreatic cancer cell lines. (a) The cell invasion was analyzed by 
incubating 35,000 cells with and without rfhSP-D (20 µg/ml) in the BioCoat™ Matrigel™ Invasion Chambers at 37°C for 22 h. The invasive cells were  
fixed and stained before mounting the membrane on the slide for cell counting. The images show the difference between treated and untreated. (b) Treatment  
with rfhSP-D significantly reduced the cell invasion as for Panc-1 (~50%) and MiaPaCa-2 (~65%). However, as anticipated, no invasion was detected in Capan-2 
cell line, neither in treated nor untreated samples. Significant values were considered based on ***p < 0.001 and ****p < 0.0001 between treated and untreated 
samples.
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cytoplasm of the rfhSP-D-treated Panc-1 and MiaPaCa-2 cell 
lines (Figure 5D). No difference was seen in Capan-2-treated and 
untreated cells (data not shown). Next, key regulators of EMT 
were examined.
rfhsP-D reduces the expression  
of eMT Markers
To determine whether exogenous rfhSP-D was affecting the key 
regulators of EMT, we examined the gene expression of Vimentin, 
Zeb1, and Snail at various time points. All of these markers were 
differentially downregulated in all the cell lines. Vimentin was 
significantly downregulated in Panc-1, ~log10 one-fold at 1  h, 
and ~log10 0.5-fold at 6 h (Figure 6A). MiaPaCa-2 showed ~log10 
0.5-fold downregulation at 1  h that remained constant at 6  h 
(Figure 6A). Vimentin downregulation occurred at a later time-
point (6  h) in Capan-2 cell line (~log10 0.5-fold) (Figure  6A). 
All cell lines showed a similar pattern of decrease in the transcript 
levels of Vimentin at 12 h compared to earlier time-points follow-
ing rfhSP-D.
Snail was significantly downregulated in Panc-1 (~log10 one-
fold), MiaPaCa-2 (~log10 0.5-fold), and Capan-2 (~log10 one-fold) 
at 1 h and remained downregulated at 6 and 12 h (Figure 6A). 
Zeb1 transcript level was significantly reduced in Panc-1 (~log10 
0.5-fold) at 1 and 6 h and MiaPaCa-2 (~log10 two-fold) at 12 h 
(Figure 6A). No difference in Zeb1 gene expression was seen in 
Capan-2. Since TGF-β regulates these EMT markers and rfhSP-D 
downregulates TGF-β, rfhSP-D mediated downregulation of 
EMT markers (Vimentin, Snail, and Zeb1) was logically evident.
Qualitative analysis of Vimentin (Figure  6B) and Zeb1 
expressions (Figure  6C) in Panc-1 and MiaPaCa-2 cell lines 
via immunofluorescence microscopy revealed a significant 
difference in the cytoplasmic presence of these proteins in the 
rfhSP-D-treated cells, as compared to untreated cells. These 
observations were consistent with flow cytometry data that was 
carried out to further validate quantitatively the downregula-
tion of the Vimentin, Zeb1, and Snail in Panc-1 and MiaPaCa-2 
cells (Figure  6D) following 24  h treatment with rfhSP-D. The 
mean fluorescence values for Vimentin, Zeb1, and Snail were 
approximately 50% less in the rfhSP-D-treated cells as compared 
to their untreated counterparts and a clear shift was seen in the 
fluorescence intensity between rfhSP-D-treated and untreated 
cells (Figure 6D).
FigUre 5 | Treatment with rfhSP-D downregulates TGF-β expression. (a) TGF-β gene expression, as determined by qPCR, was significantly downregulated at 12 h 
in both Panc-1 and MiaPaCa-2 cell lines. Significant values were considered based on ***p < 0.001 and ****p < 0.0001 between treated and untreated samples. 
(b) Western blot analysis revealed a ~60 kDa band that was very faint in the rfhSP-D-treated sample. (c) TGF-β intracellular staining for cell lines. 0.5 × 105 cells 
were incubated with and without rfhSP-D (20 µg/ml) for 24 h followed by probing with rabbit anti-human TGF-β1 antibody (1:500), and then by Alexa Fluor 488 
(1:500) and Hoechst (1:10,000). Immunofluorescence analysis showed bright green fluorescence in the cytoplasm of the untreated cells as compared to weak 
staining in the treated cells. (D) Smad 2/3 intracellular staining for Panc-1 and MiaPaCa-2 cell lines with and without rfhSP-D (20 µg/ml) treatment for 24 h using 
rabbit anti-human Smad2/3 antibody (1:500) and then probed with anti-rabbit CY3 (1:1,000) showed the presence of Smad2/3 in the cytoplasm of untreated cells; 
however, no CY3 fluorescence was detected in the rfhSP-D-treated cells.
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as early as 6 h following the rfhSP-D treatment. Interestingly, 
but not surprisingly, the effect was even more pronounced 
when rfhSP-D (20 µg/ml) and anti-TGF-β were added together 
(Figure 7B).
DiscUssiOn
SP-D was originally considered to be a lung-specific hydrophilic 
surfactant protein that agglutinated a diverse range of pathogens 
(viruses, bacteria, and fungi). It also acts as an opsonin, enhancing 
pathogens’ phagocytosis and subsequent killing (31). However, its 
ability to bind allergens (of Aspergillus fumigatus and house dust 
mite) and inhibit allergen IgE interaction and subsequent hista-
mine release from sensitized basophils raised the possibility that 
SP-D could be involved in dampening pulmonary hypersensitivity 
(32, 33). In a murine model of allergic hypersensitivity, 
rfhSP-D treatment lowered specific IgE level, reduced pulmonary 
and peripheral eosinophilia, and caused Th2 to Th1 polari zation 
(34). Subsequently, it was found that eosinophils deri ved from 
blocking TgF-β Via neutralizing antibody 
reduces the expression of eMT Markers 
in a Way similar to rfhsP-D
To further establish the TGF-β association, we used neutralizing 
antibody in order to block TGF-β in all cell lines and assessed 
the expression of these EMT markers. All cells lines were incu-
bated with TGF-β neutralizing antibody for 6 h and the mRNA 
expression for EMT markers (Vimentin, Snail, and Zeb1) was 
measured by qPCR. Interestingly, blocking TGF-β showed 
similar downregulation trend as seen for the rfhSP-D treatment, 
which further validated that rfhSP-D treatment caused down-
regulation of TGF-β, which in turn suppressed EMT regulators 
(Figure  7A). The images were taken for Panc-1 cell line to 
analyze the cell morphological differences following treatment 
with rfhSP-D, anti-TGF-β antibody, or rfhSP-D + anti-TGF-β 
together, to compare with those cells that were untreated at 6 h 
(Figure 7B). Less branches and cell movement were observed 
in all the treated cells as compared to the untreated control, 
which suggested that suppressed EMT effects become apparent 
FigUre 6 | Continued
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FigUre 6 | Recombinant fragment of human SP-D (rfhSP-D) downregulates the expression of epithelial-to-mesenchymal transition (EMT) markers (Vimentin, Snail, 
and Zeb1). (a) All cell lines were incubated with and without rfhSP-D (20 µg/ml) for various time points and total RNA was extracted to synthesize cDNA. Each 
qPCR reaction was carried out in triplicates and human 18S RNA, an endogenous control, was used to normalize the gene expressions. The cycle threshold mean 
was used to calculate the relative expression to compare treated and untreated. EMT inducers, Vimentin, Snail, and Zeb1, were significantly downregulated across 
all cell lines. Significant values were considered based on *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001 between treated and untreated samples. (b) 
Vimentin intracellular staining for all cell lines using 0.5 × 105 cells incubated with and without rfhSP-D (20 µg/ml) for 24 h followed by probing with rabbit anti-human 
Vimentin antibody (1:500) and then with Alexa Fluor 488 conjugated with FITC (1:500) and Hoechst (1:10,000) for immunofluorescence analysis showed bright 
green fluorescence in the cytoplasm of the untreated cells as compared to very weak staining in the rfhSP-D-treated cells. (c) Zeb1 intracellular staining for all cell 
lines using 0.5 × 105 cells incubated with and without rfhSP-D (20 µg/ml) for 24 h followed by probing with rabbit anti-human Zeb1 antibody (1:500) and then with 
Alexa Fluor 488 (1:500) and Hoechst (1:10,000) for immunofluorescence analysis showed bright green fluorescence in the cytoplasm of the untreated cells of all cell 
lines as compared to minor staining in the treated cells of Panc-1 and MiaPaCa-2. (D) The quantitative analysis of the mean fluorescence of Vimentin, Zeb1, and 
Snail of Panc-1 and MiaPaCa-2 cell lines showed a significant reduction in the rfhSP-D-treated cells as compared to untreated counterparts. Significant values were 
considered based on ****p < 0.0001 between treated and untreated samples.
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allergic patients, but not non-sensitized eosinophils derived from 
healthy subjects, underwent apoptosis when treated with rfhSP-D 
in vitro (28). An eosinophilic leukemic cell line, AML14.3D10, 
was thus examined to understand the mechanism of apoptosis 
induction by rfhSP-D (21). It revealed that levels of various apop-
totic markers, such as activated p53, cleaved caspase 9, PARP, and 
G2/M checkpoints were considerably increased following rfhSP-
D treatment, in addition to reduced levels of survival factors 
including HMGA1 (21, 35). Experiments with activated PBMCs 
also mirrored these observations (36). These studies have lent 
credence to the idea that SP-D is an innate immune surveillance 
molecule, especially outside lungs.
Hasegawa et  al. have earlier shown that by interfering with 
EGF–EGFR interaction, SP-D can downregulate EGF signaling 
in A549 and H441 human lung adenocarcinoma cells (22), thus 
suppressing proliferation, migration, and invasiveness. Recently, 
Kaur et al. have shown that rfhSP-D can induce apoptosis in a 
range of pancreatic cancer cell lines via TNF-α/Fas-mediated 
pathway irrespective of the p53 status of the cells (29). Using 
Panc-1 (p53mt), MiaPaCa-2 (p53mt), and Capan-2 (p53wt) pan-
creatic cancer cell lines, we found that rfhSP-D treatment for 
24 h caused growth arrest in G1 cell cycle phase and triggered 
upregulation of pro-apoptotic markers, TNF-α, and Fas, which 
eventually caused apoptosis by 48 h (29).
In the current study, we wanted to assess the effects of rfhSP-D 
on PDA cell lines at earlier time points of the rfhSP-D treatment 
with a view that EMT may potentially be modulated. We have ear-
lier reported that the binding of rfhSP-D to PDA cells is calcium-
dependent but not sugar-dependent. Thus, it is likely that CRDs are 
involved in binding to target ligand on the cancer cell surface via 
protein–protein interaction. As a follow up study (29), we mainly 
focused on investigating the effects of rfhSP-D on EMT on these 
cancer cells. We have earlier reported using all necessary controls 
(including BSA and full length SP-D) and experiments (cell bind-
ing and cell viability assays), which established the specificity of 
rfhSP-D. BSA did not have any effect on PDA cell lines while 
full-length native SP-D purified from the lung lavage of alveolar 
proteinosis patients, was as good as rfhSP-D (29). Due to the ease 
of the production of large amounts of rfhSP-D, compared to full 
length SP-D, we have carried out these experiments using rfhSP-D, 
which is well characterized in the literature as a potential thera-
peutic molecule.
FigUre 7 | (a) TGF-β caused downregulation of epithelial-to-mesenchymal transition (EMT) markers. All cell lines were incubated with TGF-β neutralizing antibody 
for 6 h to analyze the gene expression of Vimentin, Snail, and Zeb1, which showed that all EMT markers were downregulated in a manner similar to recombinant 
fragment of human SP-D (rfhSP-D) treatment. Significant values were considered based on ****p < 0.0001 between treated and untreated samples. (b) Analysis of 
images taken at 6 h following the treatment with rfhSP-D, anti-TGF-β, both rfhSP-D and anti-TGF-β and untreated begins to show less branches (highlighted with 
white arrows in UT) and decreased cell movement in all the treated samples as compared to untreated control, which translates into significant difference by 24 h as 
shown in cell invasion assay.
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EMT induction is characterized by morphological alterations, 
enhanced motility, reduced cell–cell contact (17), and upregula-
tion of mesenchymal markers, such as Vimentin (8), Snail (18), 
and Zeb1 (9). In this study, we report, for the first time, a novel anti-
EMT role of human SP-D, which interferes with TGF-β induced 
EMT by blocking Smad phosphorylation, using pancreatic cancer 
cell lines, Panc-1, and MiaPaCa-2, and Capan-2. The rfhSP-D treat-
ment of these cell lines for up to 24 h prevented their morphological 
alterations associated with EMT, reduced tumor cell invasion in 
the matrigel, downregulated TGF-β production, and downregu-
lated key mesenchymal gene expression, such as Vimentin, Zeb1, 
and Snail. These hierarchical observations suggested that rfhSP-D 
can attenuate the TGF-β pathway to suppress EMT.
Overexpression of TGF-β1 in tumor microenvironment 
suppresses immune surveillance and facilitates the escape, 
migration, and increased resistance to anti-tumor immune 
responses (37–39). TGF-β exerts anti-proliferative effects on 
natural killer cells and cytotoxic T  cells (40–43). TGF-β1 has 
also been shown to upregulate vascular endothelial growth 
factor (VEGF) production, thus, enhances the liver metastasis 
of pancreatic cancer by regulating angiogenesis in a mouse 
model (44). TGF-β binds to heterotetrameric receptor complex 
11
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consisting of type I (TβRI/ALK5) and type II receptors (TβRII) 
to activate downstream SMADs, which act as signal transducers 
from the receptors to the nucleus (45, 46). TGF-β expression, 
as revealed by qPCR and Western blot, was downregulated in 
Panc-1 and MiaPaCa-2 cell lines following rfhSP-D treatment. 
Capan-2 was unaffected, which may be attributed to its attenu-
ated TGF-β signaling (47), thus, this cell line acted as a negative 
control in this study. In addition, minimal presence of SMAD 
2/3 was detected in the cytoplasm and no translocation to the 
nucleus was detected in the rfhSP-D-treated cells as compared 
to untreated Panc-1 and MiaPaCa-2 cell lines. This suggested 
that the downregulation of TGF-β had prevented the recruit-
ment of SMADs, the signal transduction molecules into the 
nucleus. Previous studies have shown that TGF-β stimulation 
causes the phosphorylation of SMAD 2/3, which then accu-
mulate in nucleus to drive transcription of various target genes 
(46), including key mesenchymal markers, such as Vimentin 
(10) and Snail (10, 48) in pancreatic cancer, which regulate EMT 
by either direct or indirect effect on epithelial cell adhesion 
marker such as E-cadherin (49).
The treatment of Panc-1, MiaPaCa-2, and Capan-2 with 
rfhSP-D resulted in downregulation of Snail and Zeb1; however, 
Vimentin downregulation was only observed in Panc-1 and 
MiaPaCa-2 cells. Capan-2 has previously been shown not to 
express Vimentin (50). This suggests that due to downregula-
tion of TGF-β, phosphorylation of SMADs is affected, since no 
Smad2/3 was seen either in the cytoplasm or nucleus, which 
then further causes the downregulation of EMT inducing genes 
resulting in a static state and loss of key EMT-associated mor-
phological features. Moreover, when TGF-β was blocked for 6 h 
by a neutralizing antibody, gene expressions of Vimentin, Snail, 
and Zeb1 were downregulated similar to rfhSP-D treatment, 
re-affirming that rfhSP-D suppressed EMT by downregulating 
TGF-β pathway. These results, thus, explain the significantly 
reduced invasion of rfhSP-D-treated Panc-1 and MiaPaCa-2 in 
the matrigel matrix pre-coated with extracellular matrix proteins 
that promotes invasion, whereas the non-invasive Capan-2 cells 
remained unaffected.
In a previous study, stable and short hairpin RNA-mediated 
Zeb1-knockdown in Panc-1 and MiaPaCa-2 cells with overex-
pressed Zeb1 showed a reduced sphere formation, a hallmark of 
self-renewal and differentiation (9). In addition, Zeb1 knock-out 
in orthotopic mouse xenograft models significantly affected the 
tumor growth and EMT by switching the expression of Vimentin 
and E-cadherin (9). Similarly, downregulation of Snail in Panc-1 
cells has been shown to increase its sensitivity to chemotherapeu-
tics or radiation (51). Therefore, downregulation of mesenchymal 
markers can be crucial to target the EMT driven by TGF-β 
signaling pathway, which is a critical event in the progression of 
pancreatic cancer. In view of this study, rfhSP-D offers potentially 
a novel therapeutic approach to restore the epithelial phenotype 
in pancreatic cancer. Interestingly, rfhSP-D was most effective 
in the invasive cancer cells lines, i.e., Panc-1 and MiaPaCa-2, 
unlike in the non-invasive Capan-2 cell line, which indicates 
that it selectively targets the mesenchymal-differentiated cells. 
This is consistent with previous studies where rfhSP-D did not 
affect the eosinophils derived from healthy individual whereas 
it induced apoptosis in the sensitized eosinophils from allergic 
patients (21, 28). Targeting EMT pathway using rfhSP-D could 
not only lead to decreased invasiveness but also promote drug 
sensitivity. As mentioned earlier, Zeb1 knockout Panc-1 clones 
were more susceptible to chemotherapy and their proliferation 
was significantly reduced (9). Silencing of Zeb1 in Panc-1 and 
MiaPaCa-2 cells reversed the E-cadherin expression and a sig-
nificantly increased apoptotic cell death was observed following 
gemcitabine, 5-FU, and cisplatin treatment (52). Therefore, it 
is important to explore the EMT suppressor role of rfhSP-D in 
combination with conventional chemotherapy as a therapeutic 
strategy against pre-malignant stages of solid tumor progression 
such as PDA.
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